XML 18 R7.htm IDEA: XBRL DOCUMENT v3.25.1
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY AND REDEEMABLE NONCONTROLLING INTERESTS (UNAUDITED) - USD ($)
$ in Thousands
Total
Total Charles River Laboratories, Inc. Equity
Common Stock
Additional Paid-In Capital
Retained Earnings
Accumulated Other Comprehensive Income (Loss)
Treasury Stock
Noncontrolling Interest
Beginning balance at Dec. 30, 2023 $ 56,722              
Increase (Decrease) in Temporary Equity                
Net income 1,201              
Other comprehensive income (loss), net of tax (2,763)              
Adjustment of redeemable noncontrolling interests to redemption value 4,807              
Dividends declared to noncontrolling interests (2,192)              
Ending balance at Mar. 30, 2024 57,775              
Beginning balance (in shares) at Dec. 30, 2023     51,338,000          
Beginning balance at Dec. 30, 2023 3,602,276 $ 3,596,882 $ 513 $ 1,905,578 $ 1,887,218 $ (196,427) $ 0 $ 5,394
Beginning balance (in shares) at Dec. 30, 2023             0  
Increase (Decrease) in Stockholders' Equity                
Net income 73,281 72,960     72,960     321
Other comprehensive income (loss), net of tax (53,492) (53,492)       (53,492)    
Dividends declared to noncontrolling interests 0              
Adjustment of redeemable noncontrolling interests to redemption value (4,807) (4,807)   (4,406) (401)      
Issuance of stock under employee compensation plans (in shares)     214,000          
Issuance of stock under employee compensation plans 21,505 21,505 $ 2 21,503        
Purchase of treasury shares (in shares)             42,000  
Purchase of treasury shares (9,351) (9,351)         $ (9,351)  
Stock-based compensation 16,738 16,738   16,738        
Ending balance (in shares) at Mar. 30, 2024     51,552,000          
Ending balance at Mar. 30, 2024 3,646,150 3,640,435 $ 515 1,939,413 1,959,777 (249,919) $ (9,351) 5,715
Ending balance (in shares) at Mar. 30, 2024             42,000  
Beginning balance at Dec. 28, 2024 41,126              
Increase (Decrease) in Temporary Equity                
Net income 75              
Other comprehensive income (loss), net of tax (858)              
Adjustment of redeemable noncontrolling interests to redemption value 1,320              
Ending balance at Mar. 29, 2025 $ 41,663              
Beginning balance (in shares) at Dec. 28, 2024 51,141,000   51,141,000          
Beginning balance at Dec. 28, 2024 $ 3,466,952 3,461,503 $ 511 1,966,237 1,812,100 (317,345) $ 0 5,449
Beginning balance (in shares) at Dec. 28, 2024 0           0  
Increase (Decrease) in Stockholders' Equity                
Net income $ 25,803 25,469     25,469     334
Other comprehensive income (loss), net of tax 52,099 52,099       52,099    
Adjustment of redeemable noncontrolling interests to redemption value (1,320) (1,320)   (1,320)        
Issuance of stock under employee compensation plans (in shares)     60,000          
Issuance of stock under employee compensation plans 1 1 $ 1          
Purchase of treasury shares (in shares)             2,086,000  
Purchase of treasury shares (353,132) (353,132)         $ (353,132)  
Share repurchase excise tax (3,419)              
Stock-based compensation $ 13,135 13,135   13,135        
Ending balance (in shares) at Mar. 29, 2025 49,115,000   51,201,000          
Ending balance at Mar. 29, 2025 $ 3,200,119 $ 3,194,336 $ 512 $ 1,978,052 $ 1,837,569 $ (265,246) $ (356,551) $ 5,783
Ending balance (in shares) at Mar. 29, 2025 2,086,000           2,086,000